Serum HE4 is associated with clinical prognostic factors and survival outcome in female patients with primary peritoneal carcinoma.

Mi, Dong; Zhang, Yuexiang; Chen, Shuqin

Mi, Dong; Zhang, Yuexiang; Chen, Shuqin.

Afiliación

Mi D; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, Affiliated Maternity Hospital of Nankai University, Tianjin, China.
Zhang Y; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, Affiliated Maternity Hospital of Nankai University, Tianjin, China.
Chen S; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, Affiliated Maternity Hospital of Nankai University, Tianjin, China.

Int J Gynaecol Obstet ; 158(2): 352-358, 2022 Aug.

Article en En | MEDLINE | ID: mdl-34735726

Asunto(s)

Carcinoma; Neoplasias Ováricas; Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAP/análisis; Biomarcadores de Tumor; Antígeno Ca-125; Femenino; Humanos; Neoplasia Residual; Neoplasias Ováricas/patología; Pronóstico; Proteínas/análisis

Palabras clave

CA125; human epididymis protein 4; primary peritoneal carcinoma; prognosis; recurrence; survival outcome

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Carcinoma / Proteína 2 de Dominio del Núcleo de Cuatro Disulfuros WAP Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Gynaecol Obstet Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google